Who owns Ascendis Pharma A/S, from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Artisan Partners Asset Management Inc.: 4.2% · 2,634,024 shares — Artisan Partners Holdings LP: 4.2% · 2,634,024 shares — Artisan Investments GP LLC: 4.2% · 2,634,024 shares
JANUS HENDERSON GROUP PLC: 6.0% · 3,719,452 shares
5 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Ascendis Pharma A/S.
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Ascendis Pharma A/S they hold. Together these 405 managers report 119.18% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $2.74B | 10,281,496 | 23.83% | 16.59% | June 30, 2026 |
| T. Rowe Price Investment Management, Inc. | $1.8B | 6,754,846 | 1.18% | 10.90% | June 30, 2026 |
403 more institutional holders behind a free account
See every manager reporting Ascendis Pharma A/S, how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 281 funds hold 40.66% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund | $627M | 0.95% | 4.42% | March 31, 2026 |
| MFS Mid Cap Growth Fund | $299M | 2.17% | 2.06% | February 28, 2026 |
279 more funds behind a free account
See every fund holding Ascendis Pharma A/S and what share of its net assets the position represents.
Sign up freeLoading...
